



sector #  
BOX 56Q

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTENTION:

In re Application of :

BOX: MISSING PARTS

Bertram WEISS et al.

Group Art Unit 1645

Serial No.: 09/867,753

Examiner: Unassigned

Filed: May 31, 2001

For: HUMAN PEM AS A TARGET FOR BIRTH CONTROL AND TREATMENT OF ALZHEIMER'S DISEASE

**RESPONSE TO NOTICE TO FILE MISSING PARTS**

Assistant Commissioner for Patents  
Washington, D. C. 20231

Sir:

In response to the Notice to File Missing Parts dated June 25, 2001:

- ☒ Attached is a Declaration and Power of Attorney in compliance with 37 CFR § 1.53 along with the late filing surcharge of \$130.00
- ☒ Applicant(s) include the filing fee of \$710.00.
- ☒ Applicant(s) include the extra claims fee of \$ 560.00 for 7 independent claims in excess of 3 \$80.00per additional claim.
- ☒ Applicant(s) include an executed assignment and Recordation Form Cover Sheet with the recordation fee of \$40.00 (Check No. 21720).
- ☒ Attached is a copy of the Notice to File Missing Parts.
- ☐ Applicant(s) request that the time for taking action in this case be extended pursuant to 37 CFR 1.136(a) for a period of one/two/three/four/five month(s) along with the fee of \$110.00/\$390.00/\$890.00/\$1390.00/\$1890.00.
- ☐ Applicant(s) are entitled to small entity status.
- ☐ Attached is a verified English translation of the language text filed on along with the fee of \$130.00.
- ☐ Applicant(s) provide the inventor(s) names and addresses as follows: (1) (Name), (City) and (State) along with the \$50/\$25 surcharge.
- ☒ Attached is the Sequence Disclosure as required.

- ☐ Attached is the Substitute Specification as required.
- ☐ Attached are the substitute drawings as required.

Attached is a check in the amount of \$ 1,400.00. However, the Commissioner is hereby authorized to charge fees under 37 CFR § 1.16 and § 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

*Anthony J. Zelano* Reg # 32,004

---

Anthony J. Zelano  
Registration No. 27,969  
Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO  
& BRANIGAN, P.C.  
Arlington Courthouse Plaza I  
2200 Clarendon Blvd. Suite 1400  
Arlington, Virginia 22201  
Telephone: (703)243-6333  
Facsimile: (703) 243-6410

Attorney Docket No.: SCH-1810

Date: August 24, 2001



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In application of:

Bertram Weiss et al.

**BOX SEQUENCE**

Serial No.: 09/867,753

Examiner:

Filed: May 31, 2001

Group Art Unit:

For: HUMAN PEM AS A TARGET FOR BIRTH CONTROL AND TREATMENT OF  
ALZHEIMER'S DISEASE


**RESPONSE TO NOTICE TO COMPLY  
WITH SEQUENCE DISCLOSURE REQUIREMENTS**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

This paper is responsive to the Communication from the Examiner dated June 25, 2001. SEQ ID NOS. 1-3 are assigned according to the application as filed, while SEQ ID NOS. 4-6 are included in the attached page 13 to be substituted in the specification. A copy of the sequence listing in computer readable form, along with a statement, is also being provided.

Respectfully submitted,

  
\_\_\_\_\_  
Anthony J. Zelano  
Registration No. 27,969  
Attorney for Applicant(s)

MILLEN, WHITE, ZELANO,  
& BRANIGAN, P.C.  
Arlington Courthouse Plaza I, Suite 1400  
2200 Clarendon Boulevard  
Arlington, Virginia 22201  
Telephone: (703) 243-6333  
Facsimile: (703) 243-6410

Attorney Docket No.: SCH-1810  
Filed: August 24, 2001

### Example

The expression of the human PEM in various brain tissues was analyzed by semi-quantitative PCR. To this end, the following primers were used:

Sense 5'-ATGGCGCGTTCGCTCGTCCACGAC-3', (SEQ ID NO 4)

Antisense 5'-TAGTCCACGACGATGTAGACACAG-3'. (SEQ ID NO 5)


In the control, specific primers for beta-actin were used:

Sense primer 5'-CTAGAAGCATTTCGCGGTGGACGATGGAGGG-3', (SEQ ID NO 6)

Antisense primer 5'-CTAGAAGCATTTCGCGGTGGACGATGGAGGG-3'. (SEQ ID NO 6)

The cDNA was acquired by Invitrogen (Carlsbad, CA, USA).

The PCR analysis was performed with the Advantage-2 PCR kit (Clontech). The reaction conditions were as follows: initially 5 minutes at 95°C; then 30 cycles with 95°C for 30 seconds, 62°C for 30 seconds and 72°C for 1 minute; finally 72°C for 7 minutes. The results show an elevated expression of human PEM in the frontal and temporal lobes in Alzheimer patients in comparison to healthy tissue.



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/867,753	05/31/2001	Bertram Weiss	SCH-1810

CONFIRMATION NO. 5703

23599  
MILLEN, WHITE, ZELANO & BRANIGAN, P.C.  
2200 CLARENDON BLVD.  
SUITE 1400  
ARLINGTON, VA 22201

## FORMALITIES LETTER



\*OC000000006224470\*

Date Mailed: 06/25/2001

## NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

08/29/2001 SBIRETA1 00000031 09867753

FILED UNDER 37 CFR 1.53(b)

01 FC:101	710.00 DP
02 FC:101	560.00 DP
03 FC:101	130.00 DP

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The statutory basic filing fee is missing.  
*Applicant must submit \$ 710 to complete the basic filing fee and/or file a small entity statement claiming such status (37 CFR 1.27).*
- Total additional claim fee(s) for this application is \$560.  
    ■ \$560 for 7 independent claims over 3 .
- The oath or declaration is missing.  
*A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.*
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- **The balance due by applicant is \$ 1400.**
- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b),

or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

**For questions regarding compliance to these requirements, please contact:**

- **For Rules Interpretation, call (703) 308-4216**
- **To Purchase PatentIn Software, call (703) 306-2600**
- **For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)**

*A copy of this notice MUST be returned with the reply.*

  
\_\_\_\_\_  
Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE